Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
TUROCTOCOG ALFA
NOVO NORDISK CANADA INC
B02BD02
COAGULATION FACTOR VIII
250UNIT
KIT
TUROCTOCOG ALFA 250UNIT
INTRAVENOUS
4ML
Schedule D
HEMOSTATICS
Active ingredient group (AIG) number: 0156330001; AHFS:
APPROVED
2014-12-04
_ZONOVATE® Product Monograph _ _Page 1 of 38_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION ZONOVATE ® Antihemophilic Factor (Recombinant, B-Domain Truncated) turoctocog alfa Lyophilized Powder 250, 500, 1000, 1500, 2000 and 3000 IU/vial Intravenous injection ATC code: B02BD02 Blood Coagulation Factor VIII Novo Nordisk Canada Inc. 101-2476 Argentia Road Mississauga, Ontario L5N 6M1 Canada Date of Initial Approval: December 08, 2014 Date of Revision: April 12, 2021 Submission Control No: 239150 _ _ _ZONOVATE_ _®_ _ Product Monograph _ _Page 2 of 38_ RECENT MAJOR LABEL CHANGES 7 Warnings and Precautions 03/2021 TABLE OF CONTENTS ............................................................. Error! Bookmark not defined. PART I: HEALTH PROFESSIONAL INFORMATION ....................................................... 4 1 INDICATIONS ........................................................................................................... 4 1.1 Pediatr ics.............................................................................................................4 1.2 Ger iatr ics.............................................................................................................4 2 CONTRAINDICATIONS ........................................................................................... 4 3 DOSAGE AND ADMINISTRATION ......................................................................... 4 3.1 Dosing Considerations .........................................................................................4 3.2 Recommended Dose and Dosage Adjustment .......................................................5 3.3 Administration.....................................................................................................6 3.4 Reconstitution......................................................................................................7 3.5 Missed Dose ........................................................................................................7 4 OVERDOSAGE .................. Կարդացեք ամբողջական փաստաթուղթը